Skip to main content
PLOS One logoLink to PLOS One
. 2023 Jun 13;18(6):e0287046. doi: 10.1371/journal.pone.0287046

Severe fluctuation in mean perfusion pressure is associated with increased risk of in-hospital mortality in critically ill patients with central venous pressure monitoring: A retrospective observational study

Yudie Peng 1,#, Buyun Wu 1,#, Changying Xing 1, Huijuan Mao 1,*
Editor: Karthik Raghunathan2
PMCID: PMC10263335  PMID: 37310966

Abstract

Background

The mean perfusion pressure (MPP) was recently proposed to personalize tissue perfusion pressure management in critically ill patients. Severe fluctuation in MPP may be associated with adverse outcomes. We sought to determine if higher MPP variability was correlated with increased mortality in critically ill patients with CVP monitoring.

Methods

We designed a retrospective observational study and analyzed data stored in the eICU Collaborative Research Database. Validation test was conducted in MIMIC-III database. The exposure was the coefficient of variation (CV) of MPP in the primary analyses, using the first 24 hours MPP data recorded within 72 hours in the first ICU stay. Primary endpoint was in-hospital mortality.

Results

A total of 6,111 patients were included. The in-hospital mortality of 17.6% and the median MPP-CV was 12.3%. Non-survivors had significantly higher MPP-CV than survivors (13.0% vs 12.2%, p<0.001). After accounting for confounders, the highest MPP-CV in decile (CV > 19.2%) were associated with increased risk of hospital mortality compared with those in the fifth and sixth decile (adjusted OR: 1.38, 95% Cl: 1.07–1.78). These relationships remained remarkable in the multiple sensitivity analyses. The validation test with 4,153 individuals also confirmed the results when MPP-CV > 21.3% (adjusted OR: 1.46, 95% Cl: 1.05–2.03).

Conclusions

Severe fluctuation in MPP was associated with increased short-term mortality in critically ill patients with CVP monitoring.

Background

Adequate organ perfusion is essential for human, with mean arterial pressure (MAP) as a substitute index for blood perfusion of terminal organs [1]. However, MAP has some physiological deficiencies, especially the failure to consider venous outflow pressure. Central venous pressure (CVP), an indicator of the outflow pressure, remains the most commonly used variable to monitor fluid status and guide fluid resuscitation for critically ill patients [2], especially for those who experience severe trauma, shock, acute circulatory failure, all kinds of major operations and rapid fluid resuscitation [3]. Obtained by calculating the difference between MAP and CVP, mean perfusion pressure (MPP) was recently proposed to personalize tissue perfusion pressure management instead of MAP in critically ill patients [4, 5]. The formula can be expressed as MPP = MAP–CVP. As a novel marker for perfusion pressure, lower MPP was associated with acute kidney injury [69], but more knowledge about MPP is warranted.

As an inherent physiological property, the fluctuation of MPP existed and is theoretically associated with outcomes of critically ill patients. In effect, MPP is determined approximately by the product of cardiac output (CO) and systemic vascular resistance (SVR) [7, 10, 11]. Any circulatory condition that affects either of the two factors also affects the fluctuation of MPP. Therefore, a severe fluctuation in MPP, which represents severe hemodynamic instability, may be associated with an adverse prognosis such as deterioration of renal function [12]. Up to now, the threshold at which MPP variability (MPPV) to be clinically significant and the population who are more susceptible to abnormal variability remains unclear.

Therefore, we sought to describe the distribution of MPPV among critically ill patients with CVP monitoring and explore the relationship between MPPV and hospital mortality. We hypothesized that higher MPPV was correlated with increased risk of short-term mortality in these patients.

Methods

Study population

This study utilized data stored in the eICU Collaborative Research Database (eICU-CRD) v2.0 [13], a unique and publicly accessible multicenter database covering more than 200,000 ICU admissions. The data stored in the database was collected through the Philips eICU program, a critical care telehealth program that delivers information to caregivers at the bedside. Vital signs were generally interfaced as 1-minute averages, and archived into the database as 5-minute median values [14]. The inclusion criteria were (1) age 16 years or more; (2) at least 24 hours of continuous MAP and CVP invasive monitoring within the first 72 hours in the first ICU stay and (3) at least 20 MPP readings in the daytime and at least seven in the nighttime [15]. Daytime is defined as 7 am to 11 pm, otherwise as nighttime. Those who received dialysis, died during the first 24 hours, were complicated with chronic kidney disease stage 5, intracranial hypertension, abdominal compartment syndrome and with incomplete data or extreme MPP data were excluded. Extreme MPP refers to the values of MAP not between 0 mmHg to 150 mmHg, and the values of CVP not between -10 mmHg to 50 mmHg. Patients with CKD stage 5 were excluded because they may undergo dialysis, which will significantly affect MPP and increase variability.

Data extraction

We extracted MPP data, demographic data, baseline ICU characteristics, Charlson comorbidity index [16], and admission illness severity score (the Sequential Organ Failure Assessment (SOFA) [17]). Criteria for sepsis were defined based on those described earlier by Angus et al [18] instead of sepsis 3.0 because most microbiology data was unavailable in eICU-CRD. Additionally, the need for mechanical ventilation, the incidence of AKI, use of vasopressor, antihypertensive drugs, and sedatives were also collected. As MPP is a dynamic process, time-weighted average MPP (TWA-MPP) during the first 24 hours of ICU stay was calculated as the area under the MPP–versus–time plot as follows to truly reflect the average level of MPP.

TWA=[(t2t1)(X1+X2)/2+(t3t2)(X2+X3)/2++(tntn1)(Xn1+Xn)/2]/(tnt1)

where Xn is the value of the variable of interest at the timepoint tn.

Data cleaning

We chose the values of MAP between 0 mmHg and 150 mmHg, and the values of CVP between -10 mmHg and 50 mmHg.

Exposure

Short-term MPPV was measured as the coefficient of variation (CV) of 24-hour MPP data (MPP-CV), defined as the standard deviation (SD) divided by the mean MPP value.

Outcomes

The primary outcome was in-hospital mortality.

Statistical analysis

This is a post hoc analysis. Statistical analyses were performed using R version 3.63 (R Foundation for Statistical Computing, Vienna, Austria; www.r-project.org). Firstly, the baseline characteristics were compared between survivors and non-survivors. Categorical variables were presented as percentages and compared using a chi-square test. Continuous variables were expressed as median (25th, 75th percentile) and compared using Wilcoxon rank-sum test. To get a better understanding of the relationship between MPPV and TWA-MPP as well as other blood pressure variability (BPV), we used correlation matrices to show the correlation coefficient and then analyzed the association between MAP variability (MAPV) and prognosis.

Secondly, generalized additive models with a logit link function were built to plot associations between MPP-CV and in-hospital mortality, adjusted by age, gender, BMI, ethnicity, Charlson comorbidity index, SOFA score, admission type (elective surgery, emergency surgery or medicine), cardiovascular surgery, history of tachyarrhythmia, sepsis, incidence of AKI in the first day of ICU admission, the need for mechanical ventilation, the use of vasopressor, antihypertensive drug, sedatives, and TWA-MPP.

Thirdly, taking MPP-CV as classification variables, we used multivariable logistic regression models to assess the relationship between the hospital mortality and deciles of each parameter in which the median two deciles, the fifth decile together with the sixth decile, were chosen as reference. The multivariable logistic regression models were adjusted by the same variables mentioned above.

Subgroup and sensitivity analyses

Subgroup analyses of increased MPP-CV were conducted in patients who were male or female, elderly (age ≥ 65 years) or not, with or without hypertension, sepsis, higher than median SOFA score or not on the first day of ICU admission, admission type (surgical or medical), cardiovascular surgery or not.

Variation independent of the mean (VIM) [19] of 24-hour MPP data (MPP-VIM) was also analyzed in the sensitivity analyses. Both of the two indicators (CV and VIM) are considered to be relatively independent of the mean value [19]. Detailed formulas are displayed in S1 Table. Furthermore, as circadian rhythm exists in blood pressure, the association between daytime or nighttime MPP-CV and hospital mortality were also analyzed to observe whether the association between MPPV and prognosis is solely contributed by daytime or nighttime MPPV. Finally, based on the median MPP-CV (12%) during the first 12 hours of the 24 hours, we categorized the patients into initial low variability (MPP-CV < 12% in the first 12 hours of the 24 hours) groups and initial high variability (MPP-CV > 12% in the first 12 hours of the 24 hours) groups. Based on the MPP-CV in the second 12 hours of the 24 hours, the initial low variability group was further categorized into persistently low (MPP-CV < 12% in the second 12 hours of the 24 hours) group (group 1) and increasing (MPP-CV > 12% in the second 12 hours of the 24 hours) group (group 2); the initial high variability group was further categorized into decreasing (MPP-CV < 12% in the second 12 hours of the 24 hours) group (group 3) and persistently high (MPP-CV > 12% in the second 12 hours of the 24 hours) group (group 4). By grouping, we tried to observe the difference of hospital mortality under different change modes.

There were missing values for body mass index (BMI) (3.2%) and multiple imputation was used to handle the missing values with the mice package in R. For all analyses, a two-tailed P value less than 0.05 was considered statistically significant.

Validation test

The Medical Information Mart for Intensive Care (MIMIC)-III [20, 21] database (version v1.4) covers 46,476 patients out of 61,532 ICU admissions from 2001 to 2012 at the Beth Israel Deaconess Medical Center in Boston, MA, USA. Vital signs measurements were made at the bedside about one data point per hour. Based on the same inclusion and exclusion criteria, we conducted the validation test on patients from MIMIC-III.

Ethics approval and consent to participate

The study was conducted entirely on the publicly available, third-party anonymous public databases. The ethics committee of our hospital waived the requirement for approval of this study (2021-QT-08). To apply for access to the database, we completed the National Institutes of Health’s web-based course and passed the Protecting Human Research Participants exam (record ID. 32559175, ID. 38120064). All methods were performed in accordance with the relevant guidelines and regulations.

Results

Patient characteristics

After reviewing 166,355 first ICU stays in eICU-CRD, we finally included 6,111 fulfilling the inclusion and exclusion criteria (Fig 1). The baseline characteristics between survivors and non-survivors are shown in Table 1. The survivors were, on average, younger, predominantly male and higher in BMI. Non-survivors were significantly complicated with more comorbidities, more severe in SOFA score, needing more support (mechanical ventilation and vasopressor), less antihypertensive drug use, higher incidence of AKI and sepsis, and lower MPP compared with survivors. More non-survivors had a tachyarrhythmia history and less use of sedatives, but the difference did not reach statistical significance. Other information about hospitals, initial diagnosis, comorbidities, and MPP data of the whole cohort was listed in S2 Table.

Fig 1. Patient flow chart.

Fig 1

Table 1. Baseline characteristics of the study population in the first 24 hours and MPP characteristics of the exposure time among survivors and non-survivors.

Variables Survivors Non-Survivors p
N 5034 1077
Age 66 (56, 75) 68 (57, 77) <0.001
Male (%) 3064 (60.9) 615 (57.1) 0.024
BMI (kg/m2) 28.6 (24.6, 33.5) 28.2 (23.6, 33.6) 0.019
White (%) 3809 (75.7) 851 (79.0) 0.021
Charlson 1 (0, 2) 1 (0, 3) 0.006
SOFA score 8 (6, 10) 10 (8, 13) <0.001
Admission type <0.001
    Medicine 2190 (43.5) 821 (76.2)
    Elective surgery 2562 (50.9) 200 (18.6)
    Urgent surgery 282 (5.6) 56 (5.2)
Cardiovascular surgery 1769 (35.1) 116 (10.8) <0.001
Sepsis (%) 972 (19.3) 365 (33.9) <0.001
History of Tachyarrhythmia (%) 674 (13.4) 169 (15.7) 0.052
First day AKI (%) 1851 (36.8) 593 (55.1) <0.001
Ventilation (%) 3526 (70.0) 882 (81.9) <0.001
Vasopressors (%) 2016 (40.0) 549 (51.0) <0.001
Sedatives (%) 2555 (50.8) 527 (48.9) 0.293
Antihypertensive drugs (%) 1726 (34.3) 255 (23.7) <0.001
Measurement times of MPP 284 (264, 288) 279 (246, 288) <0.001
TWA MPP (mmHg) 63.3 (57.8, 70.0) 60.5 (53.7, 69.0) <0.001
MPP-CV (%) 12.2 (9.9, 15.3) 13.0 (10.3, 16.8) <0.001
MPP-VIM (units) 0.40 (0.32, 0.50) 0.42 (0.33, 0.54) <0.001

Continuous variables were expressed as median (interquartile range) as the distributions are skewed and categorical variables were expressed as number (percentage).

AKI: acute kidney injury; BMI: body mass index; CV: coefficient of variation; ICU: intensive care unit; MPP: mean perfusion pressure; SOFA: Sequential Organ Failure Assessment; TWA: time weighted-average; VIM: variation independent of the mean.

The median of the MPP-CV was 12.3% in the whole cohort. The 10th and 90th percentile for MPP-CV were 8.1% and 19.2%, respectively. The non-survivors had higher MPP-CV (13.0% vs 12.2%, p<0.001) as compared with survivors.

Association with TWA-MPP and other BPV

The correlation matrix showed us that the correlation coefficient between MPP-CV and MPP-VIM was 0.98, which was very strong. There was no correlation between the two MPPV parameters and the TWA-MPP (S1 Fig). We also explored the correlation coefficients between MPPV and other BPV. Among them, MAP-CV had the highest correlation coefficient (r = 0.77, r2 = 0.60) with MPP-CV. Although CVP is also a part of MPP in calculation, the correlation between CVP-CV and MPP-CV was weak (r = 0.08, r2 = 0.006).

Association with hospital mortality

Before and after adjusting for all the confounders, we found that hospital mortality increased when the MPP-CV increased (Fig 2A). After grouping in deciles (Fig 2B), univariate logistic regression revealed that higher MPP-CV (CV > 19.2%) were related to an increase in the risk of hospital mortality compared with the fifth and sixth decile (adjusted odds ratio [OR] in the tenth decile: 1.91, 95% confidence interval [Cl]:1.51–2.41). Multivariable logistic regression also revealed an increase in the risk of hospital mortality when MPP-CV > 19.2% (adjusted OR in the tenth decile: 1.38, 95% Cl:1.07–1.78).

Fig 2. The association between MPP-CV and in-hospital mortality.

Fig 2

A. The associations between in-hospital mortality risk and MPP-CV fitted by general additive models and the histograms of MPP-CV. B. The logistic regression analyses of the associations between adjusted in-hospital mortality risk and deciles of MPP-CV, taking the median two groups (the fifth decile and the sixth decile) as reference. The above associations were adjusted by age, gender, BMI, ethnicity, Charlson comorbidity index, SOFA score, admission type (elective surgery, emergency surgery or medicine), cardiovascular surgery, history of tachyarrhythmia, sepsis, incidence of AKI in the first day of ICU admission, the need for mechanical ventilation, the use of vasopressor, antihypertensive drug, sedatives and time-weighted average MPP.

Considering the high correlation between MPPV and MAPV, we also analyzed the relationship between MAP-CV and prognosis in two databases. In eICU-CRD database, MAP-CV and mortality showed a U-shaped curve as compared to the median two deciles. In the MIMIC database, however, there was no significant correlation between increased MAP-CV and prognosis (S2 Fig). In terms of predicting hospital mortality, MPPV has a slightly advantage than MAPV (S3 Table).

Sensitivity and subgroup analyses

For the sensitivity analyses, we firstly chose MPP-VIM as another variability parameter. The median of the MPP-VIM was 0.40 units in the whole cohort. The non-survivors also had VIM (0.42 units vs 0.40 units, p<0.001) as compared with survivors. We observed a similar trend as MPP-CV in the relationship between MPP-VIM and hospital mortality (S3A Fig). Multivariable logistic regression furtherly confirmed our findings, higher MPP-VIM (VIM > 0.62 units) were related to an increase in the risk of hospital mortality compared with the fifth and sixth decile (adjusted OR in the tenth decile: 1.42, 95% Cl:1.10–1.84 (S3B Fig). Secondly, the results of the association between day and night MPP-CV and hospital mortality still showed good consistency (S4 Fig).

In the subgroup analyses (Fig 3), higher MPP-CV is associated with higher risk of in-hospital mortality in the patients with a SOFA score ≥ 8. In contrast, high MPP-CV did not increase the risk of in-hospital mortality in sepsis patients. The results drawn in MPP-VIM are consistent (S5 Fig).

Fig 3. Adjusted odds ratios and 95% CIs for hospital mortality associated with the increased MPP-CV in different subgroups.

Fig 3

Subgroup analyses of increased MPP-CV were conducted in patients who were male or female, elderly (age ≥ 65 years) or not, with or without hypertension, sepsis, higher than median SOFA score or not on the first day of ICU admission, admission type (surgical or medical), cardiovascular surgery or not. The above associations were adjusted by age, gender, BMI, ethnicity, Charlson comorbidity index, SOFA score, admission type (elective surgery, emergency surgery or medicine), cardiovascular surgery, history of tachyarrhythmia, sepsis, incidence of AKI in the first day of ICU admission, the need for mechanical ventilation, the use of vasopressor, antihypertensive drug, sedatives and time-weighted average MPP.

MPP-CV change modes

According to the MPP-CV in the two periods of the first 24 hours with MPP data recorded (0–12 hours and 12-24hours), the patients were divided into four groups (Fig 4). Most patients belonged to the persistently low variability group (N = 2302). The decreasing group had the smallest number of patients (N = 791). Patients with persistently high variability had the highest hospital mortality (21.3%), and patients with persistently low variability had the lowest hospital mortality (15.7%).

Fig 4. Different change modes of MPP-CV and the corresponding prognosis.

Fig 4

MPP-CV were expressed as median (interquartile range).

Validation test

In the cohort of MIMIC-III database, 4,153 patients were enrolled with the same inclusion and exclusion criteria (Fig 5A). Although the overall MPP-CV value of MIMIC-III cohort is slightly higher in distribution, it can still be observed that hospital mortality increased when the MPP-CV increased (Fig 5B), and the highest decile of MPP-CV (CV > 21.3%) were related to an increase in the risk of hospital mortality compared with the fifth and sixth decile (adjusted OR in the tenth decile: 1.46, 95% Cl:1.05–2.03) (Fig 5C).

Fig 5. The validation test of MIMIC-III database.

Fig 5

Discussion

Main findings

The MPP was recently proposed to personalized management tissue perfusion pressure instead of MAP in critically ill patients. However, we knew little about the relationship between MPPV and mortality. In this multicenter, retrospective cohort study among critically ill patients with CVP monitoring, we aimed to clarify the clinically significant range of MPPV abnormalities for the first time. We found that the median MPP-CV was 13.2% in critically ill patients during the first 24 hours of CVP monitoring. And severely high MPP-CV that reached around 20% or more in two cohorts, occurring in about 10% of the study participants, was associated with the increased risk of in-hospital mortality.

Implications of study findings

In our study, two variability indicators confirmed the link between high variability and increased risk of hospital mortality. In addition, the same conclusion could also be drawn when analyzing daytime and nighttime MPP-CV separately. The mortality under different variability modes also confirmed the correlation between increased MPPV and prognosis. The exposure was mainly focused on MPP-CV, an indicator of the relative scatter of the values, which is easy to calculate and understand. The risk of short-term mortality increased when MPP-CV (SD/mean) reached around 20% or more. According to our results, if a patient has an average MPP of 60 mmHg and MPP-CV < 20%, then SD should be less than 12 mmHg. That is to say, 95% of the MPP readings should be within the range of 36.5 to 83.5 mmHg (mean ± 1.96 SD) based on a hypothesis of normal distribution of the MPP. Obviously, MPP-CV of over 20% represented a severe fluctuation in MPP, but it indeed occurred in about 10% of the study population in both cohorts. Therefore, it is physiologically acceptable that avoiding severe fluctuation in MPP (MPP-CV < 20%) may be a potential target for better hemodynamic management enhancing the outcomes of these patients.

One previous study has shown that intraoperative systolic BPV was associated with short-term mortality in patients undergoing aortocoronary bypass surgery [22]. Our study mainly focused on the MPP variability in critically ill patients. Why is severe fluctuation in MPP related to adverse outcomes? In effect, MPP is determined approximately by the product of cardiac output and systemic vascular resistance [23]. Any condition of circulation that affects either of these two factors also affects the fluctuation of MPP. The change of blood volume, electrolytes, acute deterioration of cardiac function could affect the cardiac output, and the vasoactive agents, sedatives and pain could impact the SVR. Therefore, severe fluctuation of MPP indirectly represents a significant variation of management in blood volume, cardiac function, electrolytes control, use of vasoactive agents, sedatives and pain management, contributing to increased mortality risk. A global perspective pointed out that rapid changes in the infusion rate of vasoactive drugs or clinicians who desired to maintain higher blood pressure levels than expected without proper de-escalation are likely to cause serious adverse complications [24]. The relationship between positive fluid balance and the development or worsening of organ dysfunction as well as excess mortality has also been confirmed [25]. Undoubtedly, severe fluctuation of MPP represents a marker of illness severity to some extent, although the illness severity was accounted for in the multivariable models. Further randomized controlled trials are required to confirm the potential causal relationship between increased MPPV and mortality.

Interestingly, the patients with higher SOFA scores seem to be more susceptible to higher MPPV according to the subgroup analyses. Critically ill patients with SOFA ≥ 8 may be presented with a higher rate of microcirculation dysfunction. In this case, the tissue oxygen extraction capacity is lost, and a more severe or prolonged duration of hypotension will aggravate tissue hypoxia. Therefore, MPP stability management should be strengthened when treating patients with more severe multiple organ dysfunction. Our subgroup analyses also showed that higher MPPV did not associate with in-hospital mortality in patients with sepsis. Our result disagreed with a previous prospective study, which showed a correlation between early higher SBP complexity and increased risk of 28-day mortality in 51 patients with severe sepsis [26]. But their study only analyzed SBP variability on the first five-minute window. Patients with sepsis are often characterized by increased MPP and MPPV during fluid resuscitation but would not necessarily develop adverse outcomes. Various studies have shown that high short-term to long-term BPV is associated with adverse outcome in patients with hypertension [2729]. Our study further clarified the relationship between short-term blood pressure variability and poor prognosis in hypertensive population which may be related to arteriosclerosis and decreased ability to regulate blood pressure and made them more vulnerable to ischemia-reperfusion injury.

Most of the variability in MPP can be explained by MAPV. However, the correlation between MAP-CV and prognosis showed no significant difference after multiple adjustments, suggesting that MAPV was of less robustness than MPPV to predict prognosis. Although there is still controversy about fluid resuscitation under the guidance of CVP [3032], we argue that more focus should be paid to MPPV in critically ill patients with CVP monitoring, as MPP comprehensively reflects the overall perfusion [4].

Strengths and limitations

This is the first clinical investigation to explore the association between the MPPV and hospital mortality in critically ill patients. The advantage of this post hoc analysis was that both eICU-CRD and MIMIC-III databases contained comprehensive and high-quality data, which guaranteed the reliability of variability calculation. Moreover, the inclusion of the 24-hour measurement ensured that all patients were exposed to a complete diurnal cycle. Finally, we conducted sensitivity analyses and validation test to make the results robust.

Our study has some limitations. First, the post hoc analysis has its inherent defects and unavoidable bias. Second, our study population is limited to the patients with central venous pressure monitoring, who are more severely ill and cannot be extended to the whole population of critically ill patients. Third, it was hard to prove the causal relationship between MPPV and the primary endpoint as the study was observational, despite using two databases to confirm the association. The question of whether MPPV was a marker of severity of illness or a potential target to improve prognosis required randomized trials to answer. Fourth, our study did not account for advanced hemodynamic data such as cardiac index, peripheral vascular resistance and mechanical ventilation parameters like positive end-expiratory pressure.

Conclusion

Severe MPP fluctuation was associated with short-term mortality in critically ill patients with CVP monitoring. Therefore, it may need to be avoided in the management of critically ill patients.

Supporting information

S1 Fig. Correlation matrices of TWA-MPP and MPPV.

(TIF)

S2 Fig. The associations between in-hospital mortality risk and MAP-CV in both databases.

(TIF)

S3 Fig. The associations between MPP-VIM and in-hospital mortality.

(TIF)

S4 Fig. The associations between in-hospital mortality risk and daytime or nighttime MPP-CV.

(TIF)

S5 Fig. The associations between in-hospital mortality risk and MPP-VIM in validation test cohort (MIMIC-III database).

(TIF)

S6 Fig. Adjusted odds ratios and 95% CIs for hospital mortality associated with the increased MPP-VIM in different subgroups.

(TIF)

S1 Table. Calculation formula of variability parameters.

Note: n is the number of MPP readings, x¯  is the mean value and w refers to the time of each interval. For VIM, linear regression fitting log (SD) with log (x) was performed. The “k” was the exponential of β0 and the “b” was the β1 of the linear regression model.

(DOCX)

S2 Table. Other information of the study population.

Continuous variables were expressed as median (interquartile range) as the distributions are skewed and categorical variables were expressed as number (percentage). ICU: intensive care unit; MPP: mean perfusion pressure; TWA: time weighted-average.

(DOCX)

S3 Table. The comparison of the AUC between MPPV and MAPV in prediction the hospital mortality.

AUC: area under the curve; CI: confidence interval; MPPV: mean perfusion pressure variability; MAPV: mean arterial pressure variability.

(DOCX)

S1 File. Minimal data set for eICU-CRD.

(CSV)

S2 File. Minimal data set for MIMIC-III.

(CSV)

Acknowledgments

We thank for the work of researchers at the MIT Laboratory for Computational Physiology, Philips Healthcare, and their collaborators. We also thank Ph.D Jin Liu for his help in statistics.

List of abbreviations

AKI

acute kidney injury

BMI

body mass index

BP

blood pressure

BPV

blood pressure variability

CI

confidence interval

CV

coefficient of variation

CVP

central venous pressure

ICU

intensive care unit

MAP

mean arterial pressure

MPP

mean perfusion pressure

MPPV

mean perfusion pressure variability

OR

odds ratio

SBP

systolic blood pressure

SOFA

Sequential Organ Failure Assessment

TWA-MPP

time-weighted average mean perfusion pressure

VIM

variation independent of the mean

Data Availability

The datasets generated and analyzed during the current study are available in the eICU-CRD repository, DOI: 10.1038/sdata.2018.178.

Funding Statement

The present study was supported by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions (CN), General Project of the National Natural Science Foundation of China (81970639, 82151320), received by Huijuan Mao. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Packiasabapathy KS, Subramaniam B. Optimal Perioperative Blood Pressure Management. Adv Anesth. 2018;36(1):67–79. doi: 10.1016/j.aan.2018.07.003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.De Backer D, Vincent JL. Should we measure the central venous pressure to guide fluid management? Ten answers to 10 questions. Crit Care. 2018;22(1):43. doi: 10.1186/s13054-018-1959-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Scales K. Central venous pressure monitoring in clinical practice. Nurs Stand. 2010;24(29):49–55; quiz 6. doi: 10.7748/ns2010.03.24.29.49.c7629 [DOI] [PubMed] [Google Scholar]
  • 4.Saugel B, Vincent JL, Wagner JY. Personalized hemodynamic management. Curr Opin Crit Care. 2017;23(4):334–41. doi: 10.1097/MCC.0000000000000422 [DOI] [PubMed] [Google Scholar]
  • 5.Panwar R, Lanyon N, Davies AR, Bailey M, Pilcher D, Bellomo R. Mean perfusion pressure deficit during the initial management of shock—an observational cohort study. J Crit Care. 2013;28(5):816–24. doi: 10.1016/j.jcrc.2013.05.009 [DOI] [PubMed] [Google Scholar]
  • 6.Panwar R, Tarvade S, Lanyon N, Saxena M, Bush D, Hardie M, et al. Relative Hypotension and Adverse Kidney-related Outcomes among Critically Ill Patients with Shock. A Multicenter, Prospective Cohort Study. Am J Respir Crit Care Med. 2020;202(10):1407–18. doi: 10.1164/rccm.201912-2316OC [DOI] [PubMed] [Google Scholar]
  • 7.Kopitkó C, Gondos T, Fülöp T, Medve L. Reinterpreting Renal Hemodynamics: The Importance of Venous Congestion and Effective Organ Perfusion in Acute Kidney Injury. Am J Med Sci. 2020;359(4):193–205. doi: 10.1016/j.amjms.2020.01.012 [DOI] [PubMed] [Google Scholar]
  • 8.Hu R, Kalam Y, Broad J, Ho T, Parker F, Lee M, et al. Decreased mean perfusion pressure as an independent predictor of acute kidney injury after cardiac surgery. Heart Vessels. 2020;35(8):1154–63. doi: 10.1007/s00380-020-01578-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ostermann M, Hall A, Crichton S. Low mean perfusion pressure is a risk factor for progression of acute kidney injury in critically ill patients—A retrospective analysis. BMC Nephrol. 2017;18(1):151. doi: 10.1186/s12882-017-0568-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Cattermole GN, Leung PY, Ho GY, Lau PW, Chan CP, Chan SS, et al. The normal ranges of cardiovascular parameters measured using the ultrasonic cardiac output monitor. Physiol Rep. 2017;5(6). doi: 10.14814/phy2.13195 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Meng L. Heterogeneous impact of hypotension on organ perfusion and outcomes: a narrative review. Br J Anaesth. 2021;127(6):845–61. doi: 10.1016/j.bja.2021.06.048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.PYWBXCM H Increased mean perfusion pressure variability is associated with subsequent deterioration of renal function in critically ill patients with central venous pressure monitoring: a retrospective observational study. Renal failure. 2022. doi: 10.1080/0886022X.2022.2120822 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Pollard TJ, Johnson AEW, Raffa JD, Celi LA, Mark RG, Badawi O. The eICU Collaborative Research Database, a freely available multi-center database for critical care research. Sci Data. 2018;5:180178. doi: 10.1038/sdata.2018.178 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.O’Halloran HM, Kwong K, Veldhoen RA, Maslove DM. Characterizing the Patients, Hospitals, and Data Quality of the eICU Collaborative Research Database. Crit Care Med. 2020;48(12):1737–43. doi: 10.1097/CCM.0000000000004633 [DOI] [PubMed] [Google Scholar]
  • 15.Parati G, Stergiou G, O’Brien E, Asmar R, Beilin L, Bilo G, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359–66. doi: 10.1097/HJH.0000000000000221 [DOI] [PubMed] [Google Scholar]
  • 16.Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–51. doi: 10.1016/0895-4356(94)90129-5 [DOI] [PubMed] [Google Scholar]
  • 17.Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707–10. doi: 10.1007/BF01709751 [DOI] [PubMed] [Google Scholar]
  • 18.Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303–10. doi: 10.1097/00003246-200107000-00002 [DOI] [PubMed] [Google Scholar]
  • 19.Park S, Lee HC, Jung CW, Choi Y, Yoon HJ, Kim S, et al. Intraoperative Arterial Pressure Variability and Postoperative Acute Kidney Injury. Clin J Am Soc Nephrol. 2020;15(1):35–46. doi: 10.2215/CJN.06620619 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Johnson AE, Pollard TJ, Shen L, Lehman LW, Feng M, Ghassemi M, et al. MIMIC-III, a freely accessible critical care database. Sci Data. 2016;3:160035. doi: 10.1038/sdata.2016.35 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Johnson AE, Stone DJ, Celi LA, Pollard TJ. The MIMIC Code Repository: enabling reproducibility in critical care research. J Am Med Inform Assoc. 2018;25(1):32–9. doi: 10.1093/jamia/ocx084 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Aronson S, Stafford-Smith M, Phillips-Bute B, Shaw A, Gaca J, Newman M. Intraoperative systolic blood pressure variability predicts 30-day mortality in aortocoronary bypass surgery patients. Anesthesiology. 2010;113(2):305–12. doi: 10.1097/ALN.0b013e3181e07ee9 [DOI] [PubMed] [Google Scholar]
  • 23.Chotalia M, Ali M, Hebballi R, Singh H, Parekh D, Bangash MN, et al. Hyperdynamic Left Ventricular Ejection Fraction in ICU Patients With Sepsis. Crit Care Med. 2021. doi: 10.1097/CCM.0000000000005315 [DOI] [PubMed] [Google Scholar]
  • 24.Annane D, Ouanes-Besbes L, de Backer D, Du B, Gordon AC, Hernández G, et al. A global perspective on vasoactive agents in shock. Intensive Care Med. 2018;44(6):833–46. doi: 10.1007/s00134-018-5242-5 [DOI] [PubMed] [Google Scholar]
  • 25.O’Connor ME, Prowle JR. Fluid Overload. Crit Care Clin. 2015;31(4):803–21. doi: 10.1016/j.ccc.2015.06.013 [DOI] [PubMed] [Google Scholar]
  • 26.Tang Y, Sorenson J, Lanspa M, Grissom CK, Mathews VJ, Brown SM. Systolic blood pressure variability in patients with early severe sepsis or septic shock: a prospective cohort study. BMC Anesthesiol. 2017;17(1):82. doi: 10.1186/s12871-017-0377-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Eguchi K, Hoshide S, Schwartz JE, Shimada K, Kario K. Visit-to-visit and ambulatory blood pressure variability as predictors of incident cardiovascular events in patients with hypertension. Am J Hypertens. 2012;25(9):962–8. doi: 10.1038/ajh.2012.75 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Mulè G, Calcaterra I, Costanzo M, Morreale M, D’Ignoto F, Castiglia A, et al. Average real variability of 24-h systolic blood pressure is associated with microalbuminuria in patients with primary hypertension. J Hum Hypertens. 2016;30(3):164–70. doi: 10.1038/jhh.2015.66 [DOI] [PubMed] [Google Scholar]
  • 29.Mehlum MH, Liestøl K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM, et al. Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks. Eur Heart J. 2018;39(24):2243–51. doi: 10.1093/eurheartj/ehx760 [DOI] [PubMed] [Google Scholar]
  • 30.Marik PE, Cavallazzi R. Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. Crit Care Med. 2013;41(7):1774–81. doi: 10.1097/CCM.0b013e31828a25fd [DOI] [PubMed] [Google Scholar]
  • 31.Siegler BH, Rex S, Rossaint R, Weigand MA. Is the central venous pressure an obsolescent model or a valuable puzzle stone in haemodynamic monitoring? Eur J Anaesthesiol. 2017;34(6):396–7. doi: 10.1097/EJA.0000000000000610 [DOI] [PubMed] [Google Scholar]
  • 32.Mallat J, Reddi BJ. Do not abandon monitoring the central venous pressure during fluid resuscitation of septic shock patients. Intensive Care Med. 2018;44(11):2012–3. doi: 10.1007/s00134-018-5387-2 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Karthik Raghunathan

10 Apr 2023

PONE-D-23-05624Severe fluctuation in mean perfusion pressure is associated with increased risk of in-hospital mortality in critically ill patients with central venous pressure monitoring: a retrospective observational studyPLOS ONE

Dear Dr. Mao,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 25 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Karthik Raghunathan

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

"The present study was supported by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions (CN), General Project of the National Natural Science Foundation of China (81970639,82151320), received by Huijuan Mao."

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript. 

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

Additional Editor Comments:

The reviewers had mixed reactions to the manuscript but I am prepared to see a revised version. Please be sure to address the reviewer concerns in detail.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for the opportunity to review the manuscript, entitled “Severe fluctuation in mean perfusion pressure is associated with increased risk of in-hospital mortality in critically ill patients with central venous pressure monitoring: a retrospective observational study” It is well written and important points are clearly presented. I have the following questions and comments to the authors.

1) It seems that the authors focused on MPP-CV as a primary exposure, but there were many sensitivity analyses that may distract readers. For example, MPP-VIM was equally reported as if it is a primary exposure. All sensitivity and subgroup analyses should be concisely summarized in the sensitivity and subgroup analysis section of the results. Can the authors choose a few important sensitivity and subgroup analyses?

2) Can the authors clarify how MPP was obtained by showing an equation? Some readers may not be familiar with it.

3) The patient characteristics were not clear. The e-ICU data includes heterogenous patients. How many patients were elective admission? How many patients underwent cardiac and non-cardiac surgery? Can the authors adjust for them in the regression analysis?

4) Line 151: Was TWA-MPP adjusted? Why?

5) Line 177: This would not be an external validation. When it comes to external validation, a newly developed prediction score is going to be tested in a different dataset. If the authors can obtain the same information from MIMIC-III, two databases can be combined into one dataset.

6) In this study, looking at ICU mortality would be less important.

7) Line 161: Why daytime and nighttime MPP-CV was measured? Please clarify.

Reviewer #2: The present manuscript is an interesting study in which the authors use a large, multicenter eICU database (with external validation database) to analyze whether the coefficient of variation (CV) of mean perfusion pressure (MPP) (MPP-CV) over 24hrs within first 72hrs of ICU stay correlated with in-hospital mortality. They determined the median MPP-CV for the 2 databases. They also found that patients with high MPP-CV (especially >19%) had higher OR of in hospital mortality. They used a variety of secondary and subgroup analyses to confirm the robustness of their primary finding. They concluded that targeting fewer MPP swings in patients (~20% of average MPP) could be target for therpies. Overall, the topic is important, the manuscript is well-written, data analysis methods overall appear solid, and the findings are significant. Please see comments below for issues that should be addressed.

General comments:

1. Why were patients with CKD5 excluded? No justification is given. The authors should justify exclusions.

2. For exclusions, what does “extreme MPP were excluded” mean? The authors need to specify.

3. What were variables in multivariable model and how were they chosen?

4. Why did the authors pick MPP-CV < or > 12% as a cutoff? Justification is not given in methods though presumably due to median of MPP-CV of 12.3% in whole dataset?

5. Were any analyses pre-specified? This should be indicated in methods.

6. Why did the authors not include hypertension or baseline blood pressure in the model? This seemingly could be a major confounder as patients with hypertension would likely have wider swings in blood pressure. They do account for this in subgroup analysis, but curious why it was not included in the original model? Is this what anti-hypertension drug refers to in the figure legend? The authors should clarify.

7. Did the authors analyze any secondary outcomes? Presumably they have information regarding outcomes such as AKI, mechanical ventilation, etc. These would be meaningful additions.

Reviewer #3: The authors submit a manuscript describing a retrospective analysis of large database of critically ill patients having invasive monitoring. The focus was on mean-perfusion pressure variation (MAP-CVP) and mortality. The found that the average coefficient of variation the first 24 hrs of ICU admission was higher in non-survivors versus survivors. The highest decile of MPP CV was independently associated with mortality.

The topic of this paper is clinically interesting and consistent with other reports. I have a few comments.

1. It would be helpful for the readers to have an understanding of the unique aspects of the question of this study. That is, what new questions the study asks. They mention that there is knowledge that MPP variation is associated with adverse outcomes then how does this paper add to this body of knowledge? Interestingly, there are other data not references showing that fluctuations in BP in patients undergoing surgery is associated with adverse events (I believe the first author was Aronson, S). They did not address MPP to my knowledge.

2. Page 5 in the Methods section line 112: Readers may want to know how you defined extreme MPP data.

3. Page 6, lines 164-165: how did you decide to categorize high and low variability as MPP 12%?

4. An entrance criteria of having both direct blood pressure and CVP present may limit the external validity of the study when those measures are not present. That is why the readers need to know the reason for exclusion from analysis. One wonders what the added value of MPP versus MAP alone might be in the predictive modeling. While I agree with the rationale for MPP is there useful data on MAP CV alone? We do not know if the relationship found in this study is due to reduced perfusion per se versus just MAP or the factors that cause MAP variation. How do we know as an example this is not simply due to HFpEF? Those patients have high variability due to diastolic dysfunction.

5. Lines 292-293. MAP is the product of cardiac output and SVR. MPP is MAP -CVP.

6. Lines 350-351: Making as statement that MPP should be targeted as a means to improve outcome is not really warranted based on these data.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2023 Jun 13;18(6):e0287046. doi: 10.1371/journal.pone.0287046.r002

Author response to Decision Letter 0


17 May 2023

Dear Editor,

Thank you for inviting us to submit a revised version of our manuscript. We have revised the paper according to the reviewers’ suggestions. The revised version of the paper is attached, with highlighting where changes have been made in the manuscript.

Below are our specific responses to the reviewers’ comments.

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Response: Okay, we ensure that our manuscript meets PLOS ONE's style requirements.

2. Thank you for stating the following financial disclosure:

"The present study was supported by the Priority Academic Program Development (PAPD) of Jiangsu Higher Education Institutions (CN), General Project of the National Natural Science Foundation of China (81970639,82151320), received by Huijuan Mao."

Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed.

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

Response: Okay, we've added relevant expressions in the cover letter.

3. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

Response: Okay. In the revised version, we upload our study’s minimal data set as Supporting Information files.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

Response: Our ethics statement is written in the Methods section (line189-195).

5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Response: Okay, we include captions for Supporting Information files at the end of your manuscript.

Reviewer #1: Thank you for the opportunity to review the manuscript, entitled “Severe fluctuation in mean perfusion pressure is associated with increased risk of in-hospital mortality in critically ill patients with central venous pressure monitoring: a retrospective observational study” It is well written and important points are clearly presented. I have the following questions and comments to the authors.

1) It seems that the authors focused on MPP-CV as a primary exposure, but there were many sensitivity analyses that may distract readers. For example, MPP-VIM was equally reported as if it is a primary exposure. All sensitivity and subgroup analyses should be concisely summarized in the sensitivity and subgroup analysis section of the results. Can the authors choose a few important sensitivity and subgroup analyses?

Response: Thank for your comment. According to your suggestion, we removed MPP-VIM to the sensitivity and subgroup analyses section in the part of methods and results, and we delete the sensitivity analysis of the relationship of MPP-CV and ICU mortality.

2) Can the authors clarify how MPP was obtained by showing an equation? Some readers may not be familiar with it.

Response: Thank for your comment. We added the calculation formula of MPP in the background part (line 79-80).

3) The patient characteristics were not clear. The e-ICU data includes heterogenous patients. How many patients were elective admission? How many patients underwent cardiac and non-cardiac surgery? Can the authors adjust for them in the regression analysis?

Response: Thank for your comment. We re-extracted the type of admission and the patients who undergo cardiovascular surgery, and the proportion of the population is shown in the Table1 and supplementary table2.

Variables

Admission type

Medicine

Elective surgery

Urgent surgery

Cardiovascular surgery N (%)

3009 (49.2)

2762 (45.2)

338 (5.5)

1885 (30.8)

We then adjust for them in all the regression analyses. Specifically, age, gender, BMI, ethnicity, Charlson comorbidity index, SOFA score, admission type (elective surgery, emergency surgery or medicine), cardiovascular surgery, history of tachyarrhythmia, sepsis, incidence of AKI in the first day of ICU admission, the need for mechanical ventilation, the use of vasopressor, antihypertensive drug, sedatives, and TWA-MPP are adjusted in all the multivariable analyses.

After adding the two parameters, the main results were still robust. Except that the subgroup analysis has some difference compared with the original version. Mainly in the hypertension subgroup, after the adjustment of the two variables, the fluctuation of MPP had a more significant impact on the population with hypertension compared with those without.

4) Line 151: Was TWA-MPP adjusted? Why?

Response: Yes, TWA-MPP was adjusted. Because MPP also affects prognosis, we included TWA-MPP in the multivariable models to adjust the effect of MPP on the results.

5) Line 177: This would not be an external validation. When it comes to external validation, a newly developed prediction score is going to be tested in a different dataset. If the authors can obtain the same information from MIMIC-III, two databases can be combined into one dataset.

Response: Thank you for your comment. We corrected the expression of “external validation” to “validation test” (line 182).

6) In this study, looking at ICU mortality would be less important.

Response: Thank for your comment. We delete the sensitivity analysis of the relationship of MPP-CV and ICU mortality.

7) Line 161: Why daytime and nighttime MPP-CV was measured? Please clarify.

Response: There is a circadian rhythm in blood pressure, and the purpose of measuring nighttime and daytime MPP-CV is to observe whether the association between MPPV and prognosis is solely contributed by daytime or nighttime MPPV (line 164-167).

Reviewer #2: The present manuscript is an interesting study in which the authors use a large, multicenter eICU database (with external validation database) to analyze whether the coefficient of variation (CV) of mean perfusion pressure (MPP) (MPP-CV) over 24hrs within first 72hrs of ICU stay correlated with in-hospital mortality. They determined the median MPP-CV for the 2 databases. They also found that patients with high MPP-CV (especially >19%) had higher OR of in hospital mortality. They used a variety of secondary and subgroup analyses to confirm the robustness of their primary finding. They concluded that targeting fewer MPP swings in patients (~20% of average MPP) could be target for therpies. Overall, the topic is important, the manuscript is well-written, data analysis methods overall appear solid, and the findings are significant. Please see comments below for issues that should be addressed.

General comments:

1. Why were patients with CKD5 excluded? No justification is given. The authors should justify exclusions.

Response: Patients with CKD stage 5 may need to undergo dialysis, which will significantly affect MPP and increase variability. We have added relevant explanation to the method part (line112-113).

2. For exclusions, what does “extreme MPP were excluded” mean? The authors need to specify.

Response: Thank you for your comment. We specified extreme MPP in the part of data cleaning in the original manuscript. Extreme MPP refers to the values of MAP not between 0 mmHg to 150 mmHg, and the values of CVP not between -10 mmHg to 50 mmHg.

We have added relevant explanations in the exclusions in the revised version (line110-112).

3. What were variables in multivariable model and how were they chosen?

Response: Variables in multivariable model includes age, gender, BMI, ethnicity, Charlson comorbidity index, SOFA score, admission type (elective surgery, emergency surgery or medicine), cardiovascular surgery, history of tachyarrhythmia, sepsis, incidence of AKI in the first day of ICU admission, the need for mechanical ventilation, the use of vasopressor, antihypertensive drug, sedatives, and TWA-MPP.

These variables can be mainly divided into three parts. 1. Patients’ epidemiological information (age, gender, BMI, ethnicity),2. Severity of the diseases [Charlson comorbidity index, SOFA score, admission type (elective surgery, emergency surgery or medicine), cardiovascular surgery, history of tachyarrhythmia, sepsis, incidence of AKI in the first day of ICU admission, the need for mechanical ventilation],3.Other factors that may affect MPPV (the use of vasopressor, antihypertensive drug, sedatives, and TWA-MPP).

4. Why did the authors pick MPP-CV < or > 12% as a cutoff? Justification is not given in methods though presumably due to median of MPP-CV of 12.3% in whole dataset?

Response: Since there is no specific numerical reference from previous studies, we chose the median MPP-CV of the data set as the cut-off value (line167).

5. Were any analyses pre-specified? This should be indicated in methods.

Response: No, it is a post hoc analysis. We clarified it in the first line of the statistical analysis part (line136).

6. Why did the authors not include hypertension or baseline blood pressure in the model? This seemingly could be a major confounder as patients with hypertension would likely have wider swings in blood pressure. They do account for this in subgroup analysis, but curious why it was not included in the original model? Is this what anti-hypertension drug refers to in the figure legend? The authors should clarify.

Response: Thank you for your suggestion and we quite agree with your point of view. However, baseline blood pressure information was not available in the database.

Considering that there may be some inaccuracy in the past history of hypertension and the high rate of missed diagnosis of hypertension, we correct the actual use of antihypertensive drugs in the multivariable models.

In addition, we adjusted for TWA-MPP in the multivariable models, which corrected for the effect of MPP on the results.

Moreover, we analyzed the hypertensive population separately in the subgroup analysis (figure 3) which showed that the fluctuation of MPP had a more significant impact on the population with hypertension compared with those without.

7. Did the authors analyze any secondary outcomes? Presumably they have information regarding outcomes such as AKI, mechanical ventilation, etc. These would be meaningful additions.

Response: Thank you for your comment. We conducted another study to analyze the relationship between MPPV and AKI which has been published in the journal of Renal Failure (Peng Y, Wu B, Xing C, Mao H. Increased mean perfusion pressure variability is associated with subsequent deterioration of renal function in critically ill patients with central venous pressure monitoring: a retrospective observational study. Ren Fail. 2022;44(1):1976-1984.). The result showed that increased MPPV was associated with an increased risk of subsequent deterioration of renal function in critically ill patients with central venous pressure monitoring. Maintaining stable MPP may reduce the risk of renal function deterioration.

Reviewer #3: The authors submit a manuscript describing a retrospective analysis of large database of critically ill patients having invasive monitoring. The focus was on mean-perfusion pressure variation (MAP-CVP) and mortality. The found that the average coefficient of variation the first 24 hrs of ICU admission was higher in non-survivors versus survivors. The highest decile of MPP CV was independently associated with mortality.

The topic of this paper is clinically interesting and consistent with other reports. I have a few comments.

1. It would be helpful for the readers to have an understanding of the unique aspects of the question of this study. That is, what new questions the study asks. They mention that there is knowledge that MPP variation is associated with adverse outcomes then how does this paper add to this body of knowledge? Interestingly, there are other data not references showing that fluctuations in BP in patients undergoing surgery is associated with adverse events (I believe the first author was Aronson, S). They did not address MPP to my knowledge.

Response: Thank you for your comment. Previous studies have shown that MPP is associated with poor prognosis, but no studies have shown a correlation between MPP variability and prognosis. Variability is a characteristic of MPP which is not equal to MPP and is independent of MPP itself.

Before writing the article, we also searched PubMed for the relationship between blood pressure variability and prognosis. The variability of other blood pressure indicators is also related to prognosis, including MAPV and SBPV. However, there are many studies in this area which mainly focused on patients with hypertension or patients receiving surgery. Our article focused on the MPPV of critically ill patients in the ICU, so the article [1] on the relationship between SBPV and prognosis during surgery was not cited before. In the revised version, we cite this article in the discussion section (line292-293).

[1] Aronson S, Stafford-Smith M, Phillips-Bute B, et al. Intraoperative systolic blood pressure variability predicts 30-day mortality in aortocoronary bypass surgery patients. Anesthesiology. 2010;113(2):305-312.

2. Page 5 in the Methods section line 112: Readers may want to know how you defined extreme MPP data.

Response: Thank you for your comment. We specified extreme MPP in the part of data cleaning in the original manuscript. Extreme MPP refers to the values of MAP not between 0 mmHg to 150 mmHg, and the values of CVP not between -10 mmHg to 50 mmHg.

We have added relevant explanations in the exclusions in the revised version (line110-112).

3. Page 6, lines 164-165: how did you decide to categorize high and low variability as MPP 12%?

Response: Since there is no specific numerical reference from previous studies, we chose the median MPP-CV of the data set as the cut-off value (line167).

4. An entrance criteria of having both direct blood pressure and CVP present may limit the external validity of the study when those measures are not present. That is why the readers need to know the reason for exclusion from analysis. One wonders what the added value of MPP versus MAP alone might be in the predictive modeling. While I agree with the rationale for MPP is there useful data on MAP CV alone? We do not know if the relationship found in this study is due to reduced perfusion per se versus just MAP or the factors that cause MAP variation. How do we know as an example this is not simply due to HFpEF? Those patients have high variability due to diastolic dysfunction.

Response: Thank you for your comment.

(1) Inclusion of patients with CVP monitoring may make the results not extrapolated well. We showed the relationship between MAP-CV and prognosis in Supplementary Figure 2. In the two databases, the results showed no significant difference, suggesting that MPP-CV may be more robust in predicting hospital mortality.

Supplementary Fig.2 The associations between in-hospital mortality risk and MAP-CV in both databases.

Furthermore, in terms of predicting hospital mortality, MPPV has a slightly advantage than MAPV, which has been shown in supplementary table3.

Supplementary Table 3. The comparison of the AUC between MPPV and MAPV in prediction the hospital mortality.

AUC of MPPV (95% CI) AUC of MAPV (95% CI)

CV 0.56 (0.54-0.58) 0.50 (0.48-0.52)

VIM 0.54 (0.52-0.56) 0.50 (0.48-0.52)

In addition, correlation analysis (Supplementary Fig.1) showed that the correlation coefficient between MPP-CV and MAP-CV was 0.77, r ²= 0.60 which indicated that approximately 60% of MPP-CV can be explained by MAP-CV. Therefore, although MPP-CV is mostly determined by MAP-CV, they are not completely equivalent.

(2) We also briefly analyzed the relationship between CVP-CV and hospital mortality. The result is shown in the following figure

After adjustment, the correlation between CVP variability (CVP-CV) and in-hospital mortality was not obvious.

(3) We have included TWA-MPP in the multivariable models to adjust the effect of MPP on the results. So, we consider that the results we got were due to the variability of MPP rather than the decrease in MPP.

(4) Admittedly, HFpEF can affect blood pressure variability. But this research population is focused on critically ill patients, and is hard to obtain echocardiographic data. Based on the database, it is difficult to answer your question satisfactorily, and further research may be needed in the future.

5. Lines 292-293. MAP is the product of cardiac output and SVR. MPP is MAP -CVP.

Response: Thank you for your comment. Actually, the formula in the references [2] we quoted is indeed shown in the manuscript. In the original text, it was written as “SVR = ([(MAP–CVP]/CO) × 80)”. The detailed relationships between pressure-output-resistance are clarified in this review. [3].

[2] Chotalia M, Ali M, Hebballi R, Singh H, Parekh D, Bangash MN, et al. Hyperdynamic Left Ventricular Ejection Fraction in ICU Patients With Sepsis. Crit Care Med. 2021. 32. Meng L:

[3] Meng L, Heterogeneous impact of hypotension on organ perfusion and outcomes: a narrative review. Br J Anaesth 2021, 127(6):845-861.

6. Lines 350-351: Making as statement that MPP should be targeted as a means to improve outcome is not really warranted based on these data.

Response: Thank you for your comment. Yes, the exact value of MPP-CV may not be a target for improving prognosis, but what we meant in the original manuscript is that keeping MPP-CV < 20% as far as possible may be a target for improving prognosis, that is, severe MPP fluctuations may need to be avoided in the management of critically ill patients. We have changed our expression in the revised version (line356-359).

Attachment

Submitted filename: renamed_a6fad.docx

Decision Letter 1

Karthik Raghunathan

29 May 2023

Severe fluctuation in mean perfusion pressure is associated with increased risk of in-hospital mortality in critically ill patients with central venous pressure monitoring: a retrospective observational study

PONE-D-23-05624R1

Dear Dr. Mao,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Karthik Raghunathan

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Congratulations!

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: The authors have adjusted language and supplied additional data. Authors have satisfactorily responded to my critiques.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Acceptance letter

Karthik Raghunathan

5 Jun 2023

PONE-D-23-05624R1

Severe fluctuation in mean perfusion pressure is associated with increased risk of in-hospital mortality in critically ill patients with central venous pressure monitoring: a retrospective observational study

Dear Dr. Mao:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Karthik Raghunathan

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Correlation matrices of TWA-MPP and MPPV.

    (TIF)

    S2 Fig. The associations between in-hospital mortality risk and MAP-CV in both databases.

    (TIF)

    S3 Fig. The associations between MPP-VIM and in-hospital mortality.

    (TIF)

    S4 Fig. The associations between in-hospital mortality risk and daytime or nighttime MPP-CV.

    (TIF)

    S5 Fig. The associations between in-hospital mortality risk and MPP-VIM in validation test cohort (MIMIC-III database).

    (TIF)

    S6 Fig. Adjusted odds ratios and 95% CIs for hospital mortality associated with the increased MPP-VIM in different subgroups.

    (TIF)

    S1 Table. Calculation formula of variability parameters.

    Note: n is the number of MPP readings, x¯  is the mean value and w refers to the time of each interval. For VIM, linear regression fitting log (SD) with log (x) was performed. The “k” was the exponential of β0 and the “b” was the β1 of the linear regression model.

    (DOCX)

    S2 Table. Other information of the study population.

    Continuous variables were expressed as median (interquartile range) as the distributions are skewed and categorical variables were expressed as number (percentage). ICU: intensive care unit; MPP: mean perfusion pressure; TWA: time weighted-average.

    (DOCX)

    S3 Table. The comparison of the AUC between MPPV and MAPV in prediction the hospital mortality.

    AUC: area under the curve; CI: confidence interval; MPPV: mean perfusion pressure variability; MAPV: mean arterial pressure variability.

    (DOCX)

    S1 File. Minimal data set for eICU-CRD.

    (CSV)

    S2 File. Minimal data set for MIMIC-III.

    (CSV)

    Attachment

    Submitted filename: renamed_a6fad.docx

    Data Availability Statement

    The datasets generated and analyzed during the current study are available in the eICU-CRD repository, DOI: 10.1038/sdata.2018.178.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES